摘要
目的消化性溃疡容易并发穿孔、出血和癌变等,严重危害人类健康,幽门螺杆菌(helicobacter pylori,Hp)根除与质子泵抑制剂是治疗该疾病的常见方法,具有较高治愈率。本研究探究埃索美拉唑联合铋剂四联疗法治疗Hp阳性消化性溃疡的临床疗效。方法选取2017-01-01-2019-01-01郑州市金水区总医院收治的86例Hp阳性消化性溃疡患者为研究对象,按组间基础资料具有可比性的原则分成对照组与观察组,各43例。对照组采取奥美拉唑联合铋剂四联疗法,观察组采取埃索美拉唑联合铋剂四联疗法,比较两组治疗前后血清C反应蛋白(commercial rent planning,CRP)、白细胞介素-6(interleukin 6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、胃动素(motilin,MTL)、胃泌素(gastrin,GAS)、胆囊收缩素(cholecystokinin,CCK)、不良反应发生率及Hp感染率。结果治疗后,观察组和对照组CRP水平分别为(7.70±1.36)和(11.25±2.33)mg/L,t=8.629,P<0.001;IL-6水平分别为(9.46±2.63)和(13.79±2.72)ng/L,t=7.505,P<0.001;TNF-α水平分别为(1.03±0.44)和(2.13±0.72)μg/L,t=8.548,P<0.001,差异均有统计学意义。治疗后,观察组MTL水平为(205.73±24.15)ng/L,低于对照组的(264.06±25.32)ng/L,t=10.932,P<0.001;GAS水平为(86.54±8.43)ng/L,低于对照组的(106.74±0.98)ng/L,t=9.569,P<0.001;CCK水平为(8.87±0.78)pg/mL,高于对照组的(6.72±0.62)pg/mL,t=14.150,P<0.001。观察组Hp根除率为97.67%,高于对照组的81.40%,χ^2=4.468,P=0.014;观察组不良反应总发生率为4.65%,低于对照组的20.93%,χ^2=5.108,P=0.024。结论埃索美拉唑联合铋剂四联疗法治疗Hp阳性消化性溃疡,可有效缓解胃黏膜炎症,改善胃肠激素水平,减少不良反应发生率,提高Hp根除率。
OBJECTIVE Peptic ulcer is easy to be complicated with complications such as perforation,hemorrhage and cancer,which seriously endangers human health.Helicobacter pylori(Hp)Eradication therapy and proton pump inhibitors are common treatments for this disease and have a high cure rate.This study explored the clinical efficacy of esomeprazole combined with expectorant quadruple therapy for Hp-positive peptic ulcer.METHODS Totally 86 patients with Hppositive peptic ulcer who admitted in the hospital from January 1,2017 to January 1,2019 were selected as research subjects.All selected cases were divided into control group(43 cases)and observation group(43 cases)according to the comparable basic data.Control group was treated with omeprazole combined with bismuth-containing quadruple therapy,and observation group was given esomeprazole combined with bismuth-containing quadruple therapy.The C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),motilin(MTL),gastrin(GAS),cholecystokinin(CCK),the incidence of adverse reactions,and the Hpinfection rate were compared between two groups before and after treatment.RESULTS After treatment,the CRP of the observation group and the control group were(7.70±1.36)and(11.25±2.33)mg/L,respectively,t=8.629,P<0.001.IL-6 were(9.46±2.63)and(13.79±2.72)ng/L,t=7.505,P<0.001.TNF-αwere(1.03±0.44)and(2.13±0.72)μg/L,t=8.548,P<0.001,the difference were statistically significant.After treatment,the MTL of the observation group was(205.73±24.15)ng/L,which was lower than that of the control group(264.06±25.32)ng/L,t=10.932,P<0.001;GAS was(86.54±8.43)ng/L,lower than the control group(106.74±0.98)ng/L,t=9.569,P<0.001.CCK was(8.87±0.78)pg/ml,higher than the control group(6.72±0.62)pg/ml,t=14.150,P<0.001.The Hperadication rate of the observation group was 97.67%,which was higher than that of the control group(81.40%),χ^2=4.468,P=0.014.The total incidence of adverse reactions in the observation group was 4.65%,which was lower than that of the control group(20.93%),χ
作者
朱春华
张欢欢
ZHU Chun-hua;ZHANG Huan-huan(Department of Gastroenterology,Jinshui District General Hospital of Zhengzhou,Zhengzhou 450000,P.R.China)
出处
《社区医学杂志》
2020年第2期113-116,共4页
Journal Of Community Medicine
关键词
消化性溃疡
埃索美拉唑联合铋剂
四联疗法
胃黏膜炎症
胃肠激素
peptic ulcer
esomeprazole combined with bismuth
quadruple therapy
gastric mucosal inflammation
gastrointestinal hormone
